| Literature DB >> 20128603 |
John J G Tesmer1, Valerie M Tesmer, David T Lodowski, Henning Steinhagen, Jochen Huber.
Abstract
G protein-coupled receptor kinase 2 (GRK2) is a pharmaceutical target for the treatment of cardiovascular diseases such as congestive heart failure, myocardial infarction, and hypertension. To better understand how nanomolar inhibition and selectivity for GRK2 might be achieved, we have determined crystal structures of human GRK2 in complex with Gbetagamma in the presence and absence of the AGC kinase inhibitor balanol. The selectivity of balanol among human GRKs is assessed.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20128603 PMCID: PMC3073382 DOI: 10.1021/jm9017515
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446